Evidence map›Paper›PMID 42592327›Full record

ArticleActa pharmaceutica Sinica. B2026

H2AC19 promotes lung adenocarcinoma progression

Fuwen Zuo, Jinlong Yu, Tong Liu, Xiaorui Liu, Jilong Yin, Pengzhong Ding, Yuhan Pang, Zhengdong Luo, Xiaofeng Wang, Ling Guo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fuwen ZuoDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Jinlong YuDepartment of Clinical Pharmacology, The Second Hospital of Shandong University, Jinan 250033, China.
Tong LiuDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Xiaorui LiuDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Jilong YinAdvanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Pengzhong DingDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
Yuhan PangDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Zhengdong LuoDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Xiaofeng WangDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
Ling GuoDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China.
Yirong ZhangSchool of Chinese Language and Literature, Shandong Normal University, Jinan 250014, China.
Shuang QiShandong Center for Food and Drug Evaruation and Inspection, Jinan 250014, China.
Lutao DuDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Ziying WangDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
Fan YiDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.
Xiaoshi ZhangDepartment of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis is a hallmark of lung adenocarcinoma (LUAD) and a leading cause of mortality. Identifying potential therapeutic targets that modulate this process is of critical clinical importance. Here, we established a 12-gene risk-scoring model through bioinformatics screening and systematically delineated the molecular function of H2AC19, a previously poorly understood histone variant within this signature. Analysis of human LUAD specimens revealed elevated H2AC19 expression, which correlated positively with angiogenesis markers and advanced clinical stage and negatively with patient prognosis. Functional validation using CRISPR/Cas9 in patient-derived organoids (PDOs),

Indexed as

AngiogenesisEGR1Epigenetic regulationH2AC19Lung adenocarcinomaMMP-1P300Therapeutic target

Identifiers

PMID42592327
PMCPMC13464569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.